Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label, Single Ascending Dose Trial of a Self-Complementing Optimized Adeno-associated Virus Serotype 8 Factor IX Gene Therapy (AskBio009) in Adults With Hemophilia B

NCT01687608 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT01687608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01687608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label, Single Ascending Dose Trial of a Self-Complementing Optimized Adeno-associated Virus Serotype 8 Factor IX Gene Therapy (AskBio009) in Adults With Hemophilia B
Lead sponsor
Baxalta now part of Shire
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 11, 2013
Completion date
January 17, 2030
Enrollment
30 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b